TABLE 1.
Patient, Disease, and Treatment Characteristics
| Characteristic | No. of Patients (%) |
|---|---|
| Sex | |
| Female | 125 (30) |
| Male | 287 (70) |
| Ethnicity | |
| Asian/Pacific Islander | 52 (13) |
| Black/African-American | 3 (1) |
| Hispanic/Latino | 43 (10) |
| Other/unspecified | 9 (2) |
| White | 305 (74) |
| Initial disease site | |
| Supraglottic | 299 (73) |
| Glottic | 63 (15) |
| Subglottic | 1 (<1) |
| Transglottic | 49 (12) |
| Nodal classification | |
| N0 | 198 (48) |
| Nx | 2 (<1) |
| N1 | 58 (14) |
| N2a | 16 (4) |
| N2b | 52 (13) |
| N2c | 60 (15) |
| N3 | 26 (6) |
| Pathologic grade | |
| Well differentiated | 31 (8) |
| Moderately differentiated | 213 (52) |
| Poorly differentiated | 106 (26) |
| Unknown/unspecified | 62 (15) |
| Smoking history at diagnosis | |
| None | 16 (4) |
| Unknown/unspecified | 7 (2) |
| Positive | 389 (94) |
| Radiotherapy technique | |
| 2D/3DCRT | 343 (83) |
| IMRT | 69 (17) |
| Radiation beam energy | |
| 6 MV | 181 (43) |
| 60Co | 231 (57) |
| Mean total radiation dose ± SD, Gy | 68.7 ± 6.5 |
| Mean no. of fractions received | 42 ± 14 |
| Fractionation schedule | |
| Conventional | 262 (64) |
| Altered | 107 (26) |
| Twice daily | 43 (10) |
| Concomitant boost | |
| Radiation aim | |
| Definitive | 287 (70) |
| Postoperative | 125 (30) |
| Chemotherapy | |
| Induction + concurrent | 26 (6) |
| Concurrent | 92 (22) |
| Induction | 60 (15) |
| None | 234 (57) |
Note: All data are no. of patients (%) unless otherwise indicated.